CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Biomerieux - BIM CFD

100.95
0.65%
0.55
Low: 100.7
High: 101.3
Market Trading Hours* (UTC) Open now
Closes on Monday at 16:30

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.55
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.017913 %
Charges from borrowed part ($-0.72)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.017913%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.004309 %
Charges from borrowed part ($-0.17)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.004309%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 20%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Biomerieux SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 100.05
Open* 100.85
1-Year Change* 6.1%
Day's Range* 100.7 - 101.3
52 wk Range 77.48-109.20
Average Volume (10 days) 134.40K
Average Volume (3 months) 2.07M
Market Cap 11.91B
P/E Ratio 26.34
Shares Outstanding 118.00M
Revenue 3.59B
EPS 3.82
Dividend (Yield %) 0.84493
Beta -0.04
Next Earnings Date Sep 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 24, 2023 100.05 0.60 0.60% 99.45 100.60 98.10
Mar 23, 2023 99.35 1.50 1.53% 97.85 99.80 97.15
Mar 22, 2023 97.60 0.20 0.21% 97.40 98.45 96.25
Mar 21, 2023 97.30 -0.90 -0.92% 98.20 98.30 96.90
Mar 20, 2023 97.45 0.85 0.88% 96.60 99.15 96.00
Mar 17, 2023 96.60 -0.15 -0.16% 96.75 97.25 95.85
Mar 16, 2023 95.80 0.50 0.52% 95.30 96.45 93.60
Mar 15, 2023 93.90 -1.05 -1.11% 94.95 95.10 92.85
Mar 14, 2023 94.95 1.20 1.28% 93.75 95.75 93.35
Mar 13, 2023 93.40 0.00 0.00% 93.40 93.95 91.65
Mar 10, 2023 94.05 -2.25 -2.34% 96.30 96.50 93.80
Mar 9, 2023 96.45 2.75 2.93% 93.70 97.45 93.35
Mar 8, 2023 93.50 2.45 2.69% 91.05 93.55 90.20
Mar 7, 2023 91.85 -0.95 -1.02% 92.80 93.70 91.25
Mar 6, 2023 92.30 -0.55 -0.59% 92.85 93.10 92.00
Mar 3, 2023 92.75 0.75 0.82% 92.00 93.10 91.50
Mar 2, 2023 91.25 1.30 1.45% 89.95 91.45 89.85
Mar 1, 2023 90.80 -1.60 -1.73% 92.40 92.60 90.25
Feb 28, 2023 92.50 -0.25 -0.27% 92.75 93.25 92.00
Feb 27, 2023 93.35 -0.05 -0.05% 93.40 93.85 92.90

Biomerieux Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Cost of Revenue, Total 1580.4 1375.4 1364.5 1208.2 1119
Gross Profit 2008.7 2000.8 1753.7 1466.6 1302.3
Total Operating Expense 3001.9 2591.3 2566 2304.1 2075.2
Selling/General/Admin. Expenses, Total 954.7 815.6 789.3 749.8 643.1
Research & Development 446.6 385.8 398.8 374.3 326.9
Depreciation / Amortization 76.6 59.7 17.5 17.9 17.5
Unusual Expense (Income) -0.6 0.6
Other Operating Expenses, Total -56.4 -44.6 -4.7 -46.1 -31.3
Operating Income 587.2 784.9 552.2 370.7 346.1
Interest Income (Expense), Net Non-Operating -4.3 -11.7 -29.1 -23.8 -26.7
Other, Net -2.3 1.3 1.2 0.7 -1.9
Net Income Before Taxes 580.6 774.5 524.3 347.6 317.5
Net Income After Taxes 440.5 598.9 402.8 269.8 252.4
Minority Interest 11.8 2.9 1.7 3.1 1.1
Equity In Affiliates 0 -0.7 -0.2 0 0.2
Net Income Before Extra. Items 452.3 601.1 404.3 272.9 253.7
Net Income 452.3 601.1 404.3 272.9 253.7
Total Adjustments to Net Income 0.1 0 0.1 -0.1 2.8
Income Available to Common Excl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Income Available to Common Incl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Diluted Net Income 452.4 601.1 404.4 272.8 256.5
Diluted Weighted Average Shares 118.441 118.893 118.592 118.609 118.203
Diluted EPS Excluding Extraordinary Items 3.81964 5.05579 3.41 2.3 2.17
Dividends per Share - Common Stock Primary Issue 0.85 0.85 0.62 0.19 0.35
Diluted Normalized EPS 3.81964 5.05189 3.41389 2.3 2.17
Dilution Adjustment 0
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 1931.1 1658 1802 1574.2
Revenue 1931.1 1658 1802 1574.2
Cost of Revenue, Total 860.4 720 721.6 659.2
Gross Profit 1070.7 938 1080.4 915
Total Operating Expense 1641 1360.9 1383.5 1208.4
Selling/General/Admin. Expenses, Total 514.4 440.3 436.9 379.6
Research & Development 239.3 207.3 204.8 181.5
Depreciation / Amortization 51.7 24.9 44.6 8.3
Other Operating Expenses, Total -24.8 -31.6 -24.4 -20.2
Operating Income 290.1 297.1 418.5 365.8
Interest Income (Expense), Net Non-Operating 2.8 -7.1 -4.7 -7
Other, Net -3.8 1.5 1.3 0.6
Net Income Before Taxes 289.1 291.5 415.1 359.4
Net Income After Taxes 214.2 226.3 322 276.9
Minority Interest 10 1.8 1.8 1.1
Equity In Affiliates 0 0 0.2 -0.9
Net Income Before Extra. Items 224.2 228.1 324 277.1
Net Income 224.2 228.1 324 277.1
Income Available to Common Excl. Extra. Items 224.4 228 324 277.1
Income Available to Common Incl. Extra. Items 224.4 228 324 277.1
Diluted Net Income 224.4 228 324 277.1
Diluted Weighted Average Shares 118.533 118.349 119.1 118.927
Diluted EPS Excluding Extraordinary Items 1.89315 1.92651 2.7204 2.33
Dividends per Share - Common Stock Primary Issue 0.85 0 0.85 0
Diluted Normalized EPS 1.89315 1.92651 2.7204 2.33
Total Adjustments to Net Income 0.2 -0.1 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 2199.2 1661.6 1438.5 1314.4 1279.4
Cash and Short Term Investments 803.5 389.2 275 288.3 312.1
Cash 547.1 313.5 241 239.9 214.4
Cash & Equivalents 256.4 75.7 34 48.4 97.7
Total Receivables, Net 761 730.4 668.8 607.3 587
Accounts Receivable - Trade, Net 590.6 597.9 552.1 491.8 460.1
Total Inventory 634.6 541.9 494.7 418.8 380.3
Other Current Assets, Total 0.1 0.1
Total Assets 4616.8 3927.8 3781.9 3501.6 2990
Property/Plant/Equipment, Total - Net 1224.8 1068.6 1025.2 899.1 711.4
Property/Plant/Equipment, Total - Gross 2447.6 2173.3 2100.9 1899.4 1594.4
Accumulated Depreciation, Total -1222.7 -1104.7 -1075.7 -1000.5 -883.1
Goodwill, Net 669.5 629.4 652.5 619 442.7
Intangibles, Net 411.5 430.7 508.4 507.2 430.7
Long Term Investments 34.5 39.9 31.7 59.2 50.9
Note Receivable - Long Term 27.5 10.7 10.4 8 7
Other Long Term Assets, Total 49.8 86.9 115.2 94.7 67.9
Total Current Liabilities 955.8 923.8 1170.1 796.3 651.8
Accounts Payable 239.5 207.1 211.9 179.7 161.3
Accrued Expenses 317.9 327.4 283.3 262.4 219.3
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 99.7 128.9 438.6 129.1 76.9
Other Current Liabilities, Total 298.7 260.4 236.3 225.1 194.3
Total Liabilities 1493.6 1496.7 1578 1572.8 1252.4
Total Long Term Debt 362.8 352.4 153.7 524.9 391.1
Long Term Debt 362.8 352.4 153.7 524.9 391.1
Deferred Income Tax 61.1 105.8 141.2 130.5 103.8
Minority Interest 51.4 50.2 50.7 74.1 -0.9
Other Liabilities, Total 62.5 64.5 62.3 47 106.6
Total Equity 3123.2 2431.1 2203.9 1928.8 1737.6
Common Stock 12 12 12 12 12
Additional Paid-In Capital 2242.3 2204.7 1933.4 1712.2 1558.3
Retained Earnings (Accumulated Deficit) 542.5 344.7 207.9 210.1 184.1
Treasury Stock - Common -10.3 -23 -3.9 -32.8 -10.9
Other Equity, Total 336.7 -107.3 54.5 27.3 -5.9
Total Liabilities & Shareholders’ Equity 4616.8 3927.8 3781.9 3501.6 2990
Total Common Shares Outstanding 118.282 118.16 118.324 117.819 118.132
Dec 2021 Jun 2021
Total Current Assets 2199.2 1798.7
Cash and Short Term Investments 803.5 493.2
Cash 547.1 363.3
Cash & Equivalents 256.4 129.9
Total Receivables, Net 761 694.5
Accounts Receivable - Trade, Net 590.6 542.4
Total Inventory 634.6 611
Total Assets 4616.8 4157.2
Property/Plant/Equipment, Total - Net 1224.8 1135.2
Property/Plant/Equipment, Total - Gross 2447.6 2306.1
Accumulated Depreciation, Total -1222.7 -1170.8
Goodwill, Net 669.5 642.4
Intangibles, Net 411.5 426.8
Long Term Investments 62 56.6
Other Long Term Assets, Total 49.8 97.5
Total Current Liabilities 955.8 857.9
Accounts Payable 239.5 199.1
Notes Payable/Short Term Debt 0 0
Current Port. of LT Debt/Capital Leases 99.7 163.2
Other Current Liabilities, Total 616.6 495.6
Total Liabilities 1493.6 1459
Total Long Term Debt 362.8 361.5
Long Term Debt 362.8 361.5
Deferred Income Tax 61.1 124.7
Minority Interest 51.4 50.8
Other Liabilities, Total 62.5 64.1
Total Equity 3123.2 2698.2
Common Stock 12 12
Additional Paid-In Capital 2242.3 2528.8
Retained Earnings (Accumulated Deficit) 542.5 219.5
Treasury Stock - Common -10.3 -16.6
Other Equity, Total 336.7 -45.5
Total Liabilities & Shareholders’ Equity 4616.8 4157.2
Total Common Shares Outstanding 118.282 118.095
Other Current Assets, Total 0.1
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line 598.2 402.7 269.7 255.6 237.5
Cash From Operating Activities 811.1 582.8 407.9 399.7 341.3
Cash From Operating Activities 231 210.8 189.5 177 140.5
Non-Cash Items 4.6 159 45.5 12.3 31.9
Cash Taxes Paid 185.4 115.9 81.6 66.5 91.5
Cash Interest Paid
Changes in Working Capital -22.7 -189.7 -96.8 -45.2 -68.6
Cash From Investing Activities -307.3 -265.2 -282.2 -413.1 -180.4
Capital Expenditures -290.1 -277.5 -272.5 -226.4 -183.5
Other Investing Cash Flow Items, Total -17.2 12.3 -9.7 -186.7 3.1
Cash From Financing Activities -127 -176.2 -133.9 43 -52.5
Financing Cash Flow Items 0 -2.4 -23.4 0 -11.6
Total Cash Dividends Paid -73.1 -22.5 -41.3 -40.2 -39.4
Issuance (Retirement) of Stock, Net -3.8 -16.8 0 -22.3 -0.9
Issuance (Retirement) of Debt, Net -50.1 -134.5 -69.2 105.5 -0.6
Foreign Exchange Effects 39.2 -34.1 -6.1 -11.8 5.4
Net Change in Cash 416 107.3 -14.3 17.8 113.8
Dec 2021 Jun 2021
Net income/Starting Line 598.2 276
Cash From Operating Activities 811.1 285.8
Cash From Operating Activities 231 97.2
Non-Cash Items 4.6 -66.4
Cash Taxes Paid 185.4 98.1
Changes in Working Capital -22.7 -21
Cash From Investing Activities -307.3 -143.4
Capital Expenditures -290.1 -143.5
Other Investing Cash Flow Items, Total -17.2 0.1
Cash From Financing Activities -127 -73.8
Total Cash Dividends Paid -73.1 -73.1
Issuance (Retirement) of Stock, Net -3.8 -2.5
Issuance (Retirement) of Debt, Net -50.1 1.8
Foreign Exchange Effects 39.2 12.8
Net Change in Cash 416 81.4
Financing Cash Flow Items 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Mérieux Family Other Insider Investor 58.9047 69720270 0 2022-12-13 LOW
Dassault Family Other Insider Investor 4.5964 5440410 0 2022-12-13 LOW
Sofina S.A. Investment Advisor/Hedge Fund 1.7293 2046857 0 2022-12-13 LOW
Oddo BHF Asset Management S.A.S Investment Advisor/Hedge Fund 1.257 1487841 -6384 2023-01-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.0154 1201783 1769 2023-02-28 LOW
Candriam Luxembourg S.A. Investment Advisor 1.0018 1185794 -25925 2023-01-31 HIGH
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.853 1009582 -23564 2022-12-31 LOW
Biomérieux Employees Corporation 0.7268 860200 0 2022-12-13 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.67 793019 -82179 2023-02-28 LOW
La Financière de l'Echiquier Investment Advisor 0.6011 711499 -9 2022-11-30 LOW
DNCA Investments Investment Advisor 0.5926 701399 103035 2022-12-31 LOW
Capital Research Global Investors Investment Advisor 0.5746 680070 -1913 2022-12-31 LOW
Amundi Asset Management, SAS Investment Advisor/Hedge Fund 0.5726 677721 2464 2023-02-28 HIGH
Devon Equity Management Ltd. Investment Advisor 0.5578 660181 -41600 2023-01-31 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.4724 559089 -8162 2023-02-28 LOW
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund 0.4028 476806 -31331 2022-11-30 LOW
Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.361 427323 13611 2023-01-31 LOW
AXA Investment Managers Paris Investment Advisor/Hedge Fund 0.3321 393119 9376 2023-01-31 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.3259 385689 -259 2023-01-31 LOW
Stewart Investors Investment Advisor 0.2828 334721 -152 2022-08-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Trade now Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Biomerieux Company profile

About BioMerieux SA

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.

Equity composition

9/2017, 3-for-1 stock split (Factor: 3).

Industry: Laboratory Diagnostic & Testing Substances

376, chemin de l'Orme
69280

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.47 Price
+4.630% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00464

US100

12,773.80 Price
-0.310% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

27,860.25 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Oil - Crude

70.07 Price
+0.790% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee -0.0026%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading